The population of patients with cancer is rapidly expanding, and the diagnosis and
monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in …

Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …

Ibrutinib is the first-in-class Bruton tyrosine kinase (BTK) inhibitor that has revolutionized the
treatment of B cell malignancies. Unfortunately, increased incidences of cardiotoxicity have …

Cardiotoxicity, or the development of unwarranted cardiovascular side-effects of oncologic
therapies, can involve all aspects of cardiovascular disease. The development of cardiac …

Abstract Purpose of Review Bruton's tyrosine kinase inhibitors (BTKis) have changed the
treatment and prognosis of several B-cell malignancies. However, since the approval of the …

First-generation Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been associated with
an increased risk of cardiovascular toxicities. Zanubrutinib is a more selective, next …

The prognosis of cancer patients has greatly improved in the last years, owing to the
development of novel chemotherapeutic agents. However, this progress comes with an …

Zanubrutinib is a next-generation Bruton tyrosine kinase inhibitor (BTKi) designed to
minimize off-target effects associated with toxicities that have limited long-term treatment …

It seems fitting in this year of isolation and pandemic to open the Compendium on Peripheral
Vascular Diseases with the voices of patients. Gertrude Campbell was a pioneer as the first …

Lung cancer is the most common cause of cancer-related death. Although anti-angiogenesis
therapy has been effective in the treatment of nonsmall cell lung cancer (NSCLC), drug …